Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCFGP3)

Drug Name
LKA651 Drug Info
Synonyms 45605
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMCFGP3

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin (EPO) TTQG4NR EPO_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erythropoietin (EPO) DTT EPO 4.717 3.225 1 3.781
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic macular edema
ICD Disease Classification 9B71.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin (EPO) DTT EPO 5.72E-01 -0.15 -0.83
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03927690) Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Novartis.